Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells. LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™...
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance...
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody®...
• LAVA-1207 for the treatment of prostate cancer will continue as the lead program• LAVA-051 Phase 1/2a clinical trial will be discontinued• Associated cost savings and initiatives are expected to...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.18 | -10.843373494 | 1.66 | 1.6673 | 1.46 | 42160 | 1.55888286 | CS |
| 4 | -0.56 | -27.4509803922 | 2.04 | 2.06 | 1.46 | 53648 | 1.81619994 | CS |
| 12 | -0.3 | -16.8539325843 | 1.78 | 2.093 | 1.46 | 49051 | 1.77299059 | CS |
| 26 | -1.33 | -47.3309608541 | 2.81 | 2.81 | 1.46 | 59918 | 1.94191454 | CS |
| 52 | -0.02 | -1.33333333333 | 1.5 | 6.47 | 1.35 | 495807 | 2.63389956 | CS |
| 156 | -5.34 | -78.2991202346 | 6.82 | 7.89 | 1.131 | 303966 | 3.09593289 | CS |
| 260 | -10 | -87.1080139373 | 11.48 | 17.2 | 1.131 | 265955 | 3.50027133 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
